Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms : A case series
Fàbregues-Boixar i Nebot, Oriol de (Hospital Universitari Vall d'Hebron)
Viñas, Jaume (Hospital Universitari Vall d'Hebron)
Palasí Franco, Antoni (Hospital Universitari Vall d'Hebron)
Quintana, Manuel (Hospital Universitari Vall d'Hebron)
Cardona, Ignasi (Hospital Universitari Vall d'Hebron)
Auger, Cristina (Hospital Universitari Vall d'Hebron)
Vargas Blasco, Víctor (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	To present our experience with ammonium tetrathiomolybdate (ATTM) in the decoppering phase treatment of Wilson's disease (WD) with neurological symptoms. An uncontrolled longitudinal study was carried out to describe a case series of five patients diagnosed of WD with neurological symptoms in our hospital over the last 5 years and receiving ATTM for 8 (or 16) weeks. Unified Wilson's Disease Rating Scale (UWDRS), Global Assessment Scale (GAS) for WD and the Brewer-adapted Unified Huntington's Disease Rating Scale (UHDRS) for WD, magnetic resonance imaging, and monitoring for potential adverse effects were carried out in all patients before starting ATTM and 3 months later when ATTM was stopped and zinc treatment was initiated. All five patients presented neurological clinical improvement in UWDRS, GAS, and Brewer-adapted UHDRS for WD. Neuroimaging improvement was present in 2/5 patients with brain edema reduction. Mild anemia, leukopenia, and elevation of transaminases were detected in 1 patient, with complete remission after stopping ATTM for 1 week and then restarting at a half dose. ATTM could be a good treatment for the initial treatment of WD with neurological symptoms due to its high efficacy, with a lower rate of neurological deterioration than the drugs currently available, despite the potential adverse effects. Effectiveness and safety of ammonium tetrathiomolybdate in decoppering therapy for Wilson's disease with neurological symptoms, a pilot study in routine care.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Ammonium tetrathiomolybdate ; Efficacy ; Neurological symptoms ; Safety ; Wilson's disease
Published in:	Brain and behavior, Vol. 10 (march 2020) , ISSN 2162-3279

DOI: 10.1002/brb3.1596
PMID: 32202078

7 p, 848.6 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles